Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Nasdaq  >  Flex Pharma Inc    FLKS

 SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
04/24/2017 04/25/2017 04/26/2017 04/27/2017 04/28/2017 Date
3.06(c) 3.07(c) 3.56(c) 3.6(c) 3.44(c) Last
65 928 42 962 128 199 160 229 61 088 Volume
-0.65% +0.33% +15.96% +1.12% -4.44% Change
More quotes
Financials ($)
Sales 2017 2,43 M
EBIT 2017 -50,3 M
Net income 2017 -49,6 M
Debt 2017 -
Yield 2017 -
Sales 2018 7,42 M
EBIT 2018 -65,5 M
Net income 2018 -64,9 M
Debt 2018 -
Yield 2018 -
P/E ratio 2017 -
P/E ratio 2018
Capi. / Sales2017 25,4x
Capi. / Sales2018 8,33x
Capitalization 61,8 M
More Financials
Company
Flex Pharma, Inc. operates as a biotechnology company, which engages in developing treatments for exercise-associated muscle cramps, nocturnal leg cramps and spasms associated with severe neuromuscular conditions.The company was founded by Christoph Westphal and Jennifer M. Cermak on February 26,... 
More about the company
Surperformance© ratings of Flex Pharma Inc
Trading Rating : Investor Rating :
More Ratings
Latest news on FLEX PHARMA INC
04/26 FLEX PHARMA : FDA Clears Flex Pharma's FLX-787 to Commence US Phase 2 Trial in A..
04/19 FLEX PHARMA : Presents Human Efficacy Data on FLX-787 at the American Academy of..
04/13 FLEX PHARMA : Names William K. McVicar, Ph.D. as President, Research & Developme..
04/05 FLEX PHARMA, INC. (NASDAQ : FLKS) Files An 8-K Departure of Directors or Certain..
04/05 FLEX PHARMA, INC. : Change in Directors or Principal Officers (form 8-K)
04/05 FLEX PHARMA : Names William K. McVicar, Ph.D. as President, Research & Developme..
03/23 FLEX PHARMA : Newly-Published Study Reinforces Efficacy Of HOTSHOT® In Preventin..
03/09 FLEX PHARMA : to Report Fourth Quarter and Full Year 2016 Results on March 8, 20..
03/08 FLEX PHARMA : Management's Discussion and Analysis of Financial Condition and Re..
03/08 FLEX PHARMA, INC. (NASDAQ : FLKS) Files An 8-K Results of Operations and Financi..
More news
Sector news : Bio Therapeutic Drugs
04/28 REGENERON PHARMACEUTICALS : Sanofi beats profit forecasts, upbeat on prospects f..
04/28DJSanofi 1st-Quarter Net Profit Rises on Sale of Animal-Health Unit
04/27 AMGEN : Cost controls help offset lower Amgen first-quarter drug sales
04/26 New GlaxoSmithKline CEO wants fewer, bigger new drug launches
04/18 Johnson & Johnson first quarter revenue misses estimates; new forecast includ..
More sector news : Bio Therapeutic Drugs
Latest Tweets
04/26FDA OK's Flex Pharma's IND for ALS candidate FLX-787; Phase 2 study on tap fo.. 
04/26BRIEF-FDA clears Flex Pharma's FLX-787 to commence US phase 2 trial in ALS un.. 
04/21Brokerages Set Flex Pharma Inc $FLKS PT at $17.75  
04/20Fmr LLC Has $1,330,000 Position in Flex Pharma Inc $FLKS  
04/08$FLKS "FLKS Intro" on InvestorVillage message boards:  
More tweets
Qtime:19
News from SeekingAlpha
04/26 FDA OK's Flex Pharma's IND for ALS candidate FLX-787; Phase 2 study on tap fo..
04/05 New R&D chief at Flex Pharma
03/22 Flex Pharma (FLKS) Presents At Oppenheimer 27th Annual Healthcare Conference
03/08 Flex Pharma's (FLKS) CEO Christoph Westphal on Q4 2016 Results - Earnings Cal..
03/08 Midday Gainers / Losers
Advertisement
Chart FLEX PHARMA INC
Duration : Period :
Flex Pharma Inc Technical Analysis Chart | FLKS | US33938A1051 | 4-Traders
Full-screen chart
Technical analysis trends FLEX PHARMA INC
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Technical analysis
Income Statement Evolution
More Financials
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 5
Average target price 17,8 $
Spread / Average Target 416%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Christoph H. Westphal Chairman, President & Chief Executive Officer
Katharine Lindemann Chief Operating Officer
John McCabe Chief Financial Officer
Thomas C. Wessel Chief Medical Officer
William K. McVicar President-Research & Development
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
FLEX PHARMA INC-34.85%62
AMGEN, INC.11.70%120 105
CELGENE CORPORATION7.17%96 861
GILEAD SCIENCES, INC.-4.27%89 611
REGENERON PHARMACEUTIC..5.83%41 293
VERTEX PHARMACEUTICALS..60.58%29 390
More Results